Response Biomedical deal

OncoRx, which is in registration for an IPO, will make milestone payments of $750,000, and upon approval will distribute the product exclusively in the U.S. and Canada for the oncology market. RBM will sell the test to the veterinary market, and for home use, following approval. ...